Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,550.00GBp
20 Jun 2018
Change (% chg)

0.00 (+0.00%)
Prev Close
1,550.00
Open
1,556.60
Day's High
1,572.00
Day's Low
1,549.80
Volume
8,688,866
Avg. Vol
8,824,778
52-wk High
1,724.50
52-wk Low
1,235.20

Select another date:

Wed, Jun 20 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON, June 20 GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

CORRECTED-UPDATE 1-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies - a big win after regulators warned of possible birth defects from one of the two drugs.

CORRECTED-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies.

FDA finds deficiencies in Mylan's generic Advair; shares fall

Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.

UPDATE 2-FDA finds deficiencies in Mylan's generic Advair; shares fall

* Shares fall 4.5 pct after market (Adds analyst comment; updates shares)

FDA finds deficiencies in Mylan's generic Advair

June 13 U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

UPDATE 1-GSK says vaccine business president to leave by year-end

June 12 GlaxoSmithKline Plc said the president of its vaccines business, Luc Debruyne, would leave the company at the end of the year.

MEDIA-GlaxoSmithKline exploring merger, share swap with potential buyers in India - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

Regulators flag possible birth defect link to GSK's HIV drug

LONDON U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.

Select another date: